The National Institute for Health and Care Excellence (NICE) has approved the use of belantamab mafodotin, also known as Blenrep, effective from June 13, 2025, marking a significant advancement in cancer treatment.

This innovative treatment can extend the progression-free survival of myeloma patients by nearly three times compared to existing therapies.

Clinical trials have shown that when combined with bortezomib and dexamethasone, belantamab mafodotin delays disease progression by an average of three years, a stark contrast to just over a year with daratumumab.

Approximately 1,500 patients per year in England are expected to benefit from this groundbreaking therapy.

Blood cancer patients in England will be among the first globally to access this 'Trojan horse' treatment, which is designed to target cancer cells directly.

Belantamab mafodotin is administered as an infusion every three weeks, utilizing antibodies that deliver a toxic chemotherapy drug directly into cancerous plasma cells, thereby minimizing side effects.

While the treatment is generally kinder than traditional therapies, it can still cause side effects such as dry eyes and blurred vision due to residual chemotherapy.

Patient Paul Silvester, diagnosed with myeloma in July 2023, achieved remission within weeks of starting the treatment, significantly improving his quality of life.

Blood cancer charity Myeloma UK has praised the UK's leadership in myeloma treatment, highlighting the transformative potential of this drug for many patients.

Helen Knight, director of medicines evaluation at NICE, emphasized the UK's commitment to providing fast access to effective treatments while ensuring value for taxpayers.

Professor Peter Johnson from NHS England expressed optimism that this treatment will not only prolong patients' lives but also enhance their quality of life.

Experts believe that belantamab mafodotin represents a significant advancement in cancer treatment, with hopes for long-term remission rates exceeding 50% in the next five years.